<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36298472</PMID><DateRevised><Year>2022</Year><Month>10</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-393X</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>10</Issue><PubDate><Year>2022</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Vaccines</Title><ISOAbbreviation>Vaccines (Basel)</ISOAbbreviation></Journal><ArticleTitle>New Insights into SARS-CoV-2 and Cancer Cross-Talk: Does a Novel Oncogenesis Driver Emerge?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1607</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/vaccines10101607</ELocationID><Abstract><AbstractText>Since the pandemic's onset, a growing population of individuals has recovered from SARS-CoV-2 infection and its long-term effects in some of the convalescents are gradually being reported. Although the precise etiopathogenesis of post-acute COVID-19 sequelae (PACS) remains elusive, the mainly accepted rationale is that SARS-CoV-2 exerts long-lasting immunomodulatory effects, promotes chronic low-grade inflammation, and causes irreversible tissue damage. So far, several viruses have been causally linked to human oncogenesis, whereas chronic inflammation and immune escape are thought to be the leading oncogenic mechanisms. Excessive cytokine release, impaired T-cell responses, aberrant activation of regulatory signaling pathways (e.g., JAK-STAT, MAPK, NF-kB), and tissue damage, hallmarks of COVID-19 disease course, are also present in the tumor microenvironment. Therefore, the intersection of COVID-19 and cancer is partially recognized and the long-term effects of the virus on oncogenesis and cancer progression have not been explored yet. Herein, we present an up-to-date review of the current literature regarding COVID-19 and cancer cross-talk, as well as the oncogenic pathways stimulated by SARS-CoV-2.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rapti</LastName><ForeName>Vasiliki</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>3rd Department of Internal Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsaganos</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-3775-2850</Identifier><AffiliationInfo><Affiliation>1st Department of Internal Medicine, Alexandra General Hospital, 11528 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vathiotis</LastName><ForeName>Ioannis A</ForeName><Initials>IA</Initials><Identifier Source="ORCID">0000-0002-1772-5986</Identifier><AffiliationInfo><Affiliation>3rd Department of Internal Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Syrigos</LastName><ForeName>Nikolaos K</ForeName><Initials>NK</Initials><AffiliationInfo><Affiliation>3rd Department of Internal Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard School of Public Health, Boston, MA 02115, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Peifeng</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-0969-9407</Identifier><AffiliationInfo><Affiliation>Institute for Translational Medicine, Qingdao University, Qingdao 266021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poulakou</LastName><ForeName>Garyfallia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>3rd Department of Internal Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Vaccines (Basel)</MedlineTA><NlmUniqueID>101629355</NlmUniqueID><ISSNLinking>2076-393X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 sequelae</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cancer</Keyword><Keyword MajorTopicYN="N">cancer progression</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">oncogenesis</Keyword><Keyword MajorTopicYN="N">oncogenic pathways</Keyword><Keyword MajorTopicYN="N">post-acute COVID-19 sequelae</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">tumorgenesis</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>27</Day><Hour>1</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>28</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36298472</ArticleId><ArticleId IdType="pmc">PMC9611551</ArticleId><ArticleId IdType="doi">10.3390/vaccines10101607</ArticleId><ArticleId IdType="pii">vaccines10101607</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guarner J. Three Emerging Coronaviruses in Two Decades. Am. J. Clin. Pathol. 2020;153:420&#x2013;421. doi: 10.1093/ajcp/aqaa029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcp/aqaa029</ArticleId><ArticleId IdType="pmc">PMC7109697</ArticleId><ArticleId IdType="pubmed">32053148</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., Villapol S. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci. Rep. 2021;11:16144. doi: 10.1038/s41598-021-95565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Yelin D., Wirtheim E., Vetter P., Kalil A.C., Bruchfeld J., Runold M., Guaraldi G., Mussini C., Gudiol C., Pujol M., et al. Long-term consequences of COVID-19: Research needs. Lancet Infect. Dis. 2020;20:1115&#x2013;1117. doi: 10.1016/S1473-3099(20)30701-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30701-5</ArticleId><ArticleId IdType="pmc">PMC7462626</ArticleId><ArticleId IdType="pubmed">32888409</ArticleId></ArticleIdList></Reference><Reference><Citation>Stingi A., Cirillo L. SARS-CoV-2 infection and cancer: Evidence for and against a role of SARS-CoV-2 in cancer onset. BioEssays. 2021;43:e2000289. doi: 10.1002/bies.202000289.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.202000289</ArticleId><ArticleId IdType="pmc">PMC8209829</ArticleId><ArticleId IdType="pubmed">34081334</ArticleId></ArticleIdList></Reference><Reference><Citation>Alpalh&#xe3;o M., Ferreira J.A., Filipe P. Persistent SARS-CoV-2 infection and the risk for cancer. Med. Hypotheses. 2020;143:109882. doi: 10.1016/j.mehy.2020.109882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mehy.2020.109882</ArticleId><ArticleId IdType="pmc">PMC7831646</ArticleId><ArticleId IdType="pubmed">32485314</ArticleId></ArticleIdList></Reference><Reference><Citation>Bora V.R., Patel B.M. The Deadly Duo of COVID-19 and Cancer! Front. Mol. Biosci. 2021;8:643004. doi: 10.3389/fmolb.2021.643004.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.643004</ArticleId><ArticleId IdType="pmc">PMC8072279</ArticleId><ArticleId IdType="pubmed">33912588</ArticleId></ArticleIdList></Reference><Reference><Citation>Zong Z., Wei Y., Ren J., Zhang L., Zhou F. The intersection of COVID-19 and cancer: Signaling pathways and treatment implications. Mol. Cancer. 2021;20:76. doi: 10.1186/s12943-021-01363-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12943-021-01363-1</ArticleId><ArticleId IdType="pmc">PMC8126512</ArticleId><ArticleId IdType="pubmed">34001144</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Quteimat O.M., Amer A.M. The Impact of the COVID-19 Pandemic on Cancer Patients. Am. J. Clin. Oncol. 2020;43:452&#x2013;455. doi: 10.1097/COC.0000000000000712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/COC.0000000000000712</ArticleId><ArticleId IdType="pmc">PMC7188063</ArticleId><ArticleId IdType="pubmed">32304435</ArticleId></ArticleIdList></Reference><Reference><Citation>Robilotti E.V., Babady N.E., Mead P.A., Rolling T., Perez-Johnston R., Bernardes M., Bogler Y., Caldararo M., Figueroa C.J., Glickman M.S., et al. Determinants of COVID-19 disease severity in patients with cancer. Nat. Med. 2020;26:1218&#x2013;1223. doi: 10.1038/s41591-020-0979-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0979-0</ArticleId><ArticleId IdType="pmc">PMC7785283</ArticleId><ArticleId IdType="pubmed">32581323</ArticleId></ArticleIdList></Reference><Reference><Citation>Rugge M., Zorzi M., Guzzinati S. SARS-CoV-2 infection in the Italian Veneto region: Adverse outcomes in patients with cancer. Nat. Cancer. 2020;1:784&#x2013;788. doi: 10.1038/s43018-020-0104-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43018-020-0104-9</ArticleId><ArticleId IdType="pubmed">35122051</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell B., Moss C.L., Shah V., Ko T.K., Palmer K., Sylva R., George G., Monroy-Iglesias M.J., Patten P., Ceesay M.M., et al. Risk of COVID-19 death in cancer patients: An analysis from Guy&#x2019;s Cancer Centre and King&#x2019;s College Hospital in London. Br. J. Cancer. 2021;125:939&#x2013;947. doi: 10.1038/s41416-021-01500-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41416-021-01500-z</ArticleId><ArticleId IdType="pmc">PMC8366163</ArticleId><ArticleId IdType="pubmed">34400804</ArticleId></ArticleIdList></Reference><Reference><Citation>Passamonti F., Cattaneo C., Arcaini L., Bruna R., Cavo M., Merli F., Angelucci E., Krampera M., Cairoli R., Della Porta M.G., et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: A retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737&#x2013;e745. doi: 10.1016/S2352-3026(20)30251-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(20)30251-9</ArticleId><ArticleId IdType="pmc">PMC7426107</ArticleId><ArticleId IdType="pubmed">32798473</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J., Rizvi H., Preeshagul I.R., Egger J.V., Hoyos D., Bandlamudi C., McCarthy C.G., Falcon C.J., Schoenfeld A.J., Arbour K.C., et al. COVID-19 in patients with lung cancer. Ann. Oncol. 2020;31:1386&#x2013;1396. doi: 10.1016/j.annonc.2020.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2020.06.007</ArticleId><ArticleId IdType="pmc">PMC7297689</ArticleId><ArticleId IdType="pubmed">32561401</ArticleId></ArticleIdList></Reference><Reference><Citation>Derosa L., Melenotte C., Griscelli F., Gachot B., Marabelle A., Kroemer G., Zitvogel L. The immuno-oncological challenge of COVID-19. Nat. Cancer. 2020;1:946&#x2013;964. doi: 10.1038/s43018-020-00122-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s43018-020-00122-3</ArticleId><ArticleId IdType="pubmed">35121872</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell. 2011;144:646&#x2013;674. doi: 10.1016/j.cell.2011.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2011.02.013</ArticleId><ArticleId IdType="pubmed">21376230</ArticleId></ArticleIdList></Reference><Reference><Citation>Krump N.A., You J. Molecular mechanisms of viral oncogenesis in humans. Nat. Rev. Microbiol. 2018;16:684&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6336458</ArticleId><ArticleId IdType="pubmed">30143749</ArticleId></ArticleIdList></Reference><Reference><Citation>Kellogg C., Kouznetsova V.L., Tsigelny I.F. Implications of viral infection in cancer development. Biochim. Biophys. Acta Rev. Cancer. 2021;1876:188622. doi: 10.1016/j.bbcan.2021.188622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbcan.2021.188622</ArticleId><ArticleId IdType="pubmed">34478803</ArticleId></ArticleIdList></Reference><Reference><Citation>Tempera I., Lieberman P.M. Oncogenic Viruses as Entropic Drivers of Cancer Evolution. Front. Virol. 2021;1:753366. doi: 10.3389/fviro.2021.753366.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fviro.2021.753366</ArticleId><ArticleId IdType="pmc">PMC8822580</ArticleId><ArticleId IdType="pubmed">35141704</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietropaolo V., Prezioso C., Moens U. Role of Virus-Induced Host Cell Epigenetic Changes in Cancer. Int. J. Mol. Sci. 2021;22:8346. doi: 10.3390/ijms22158346.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22158346</ArticleId><ArticleId IdType="pmc">PMC8346956</ArticleId><ArticleId IdType="pubmed">34361112</ArticleId></ArticleIdList></Reference><Reference><Citation>Mesri E.A., Feitelson M.A., Munger K. Human viral oncogenesis: A cancer hallmarks analysis. Cell Host Microbe. 2014;15:266&#x2013;282. doi: 10.1016/j.chom.2014.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2014.02.011</ArticleId><ArticleId IdType="pmc">PMC3992243</ArticleId><ArticleId IdType="pubmed">24629334</ArticleId></ArticleIdList></Reference><Reference><Citation>Akram N., Imran M., Noreen M., Ahmed F., Atif M., Fatima Z., Bilal Waqar A. Oncogenic Role of Tumor Viruses in Humans. Viral Immunol. 2017;30:20&#x2013;27. doi: 10.1089/vim.2016.0109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2016.0109</ArticleId><ArticleId IdType="pubmed">27830995</ArticleId></ArticleIdList></Reference><Reference><Citation>McLaughlin-Drubin M.E., Munger K. Viruses associated with human cancer. Biochim. Biophys. Acta. 2008;1782:127&#x2013;150. doi: 10.1016/j.bbadis.2007.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2007.12.005</ArticleId><ArticleId IdType="pmc">PMC2267909</ArticleId><ArticleId IdType="pubmed">18201576</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales-S&#xe1;nchez A., Fuentes-Panan&#xe1; E.M. Human viruses and cancer. Viruses. 2014;6:4047&#x2013;4079. doi: 10.3390/v6104047.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v6104047</ArticleId><ArticleId IdType="pmc">PMC4213577</ArticleId><ArticleId IdType="pubmed">25341666</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore P.S., Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat. Rev. Cancer. 2010;10:878&#x2013;889. doi: 10.1038/nrc2961.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc2961</ArticleId><ArticleId IdType="pmc">PMC3718018</ArticleId><ArticleId IdType="pubmed">21102637</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruhne B., Sompallae R., Marescotti D., Kamranvar S.A., Gastaldello S., Masucci M.G. The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species. Proc. Natl. Acad. Sci. USA. 2009;106:2313&#x2013;2318. doi: 10.1073/pnas.0810619106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0810619106</ArticleId><ArticleId IdType="pmc">PMC2650153</ArticleId><ArticleId IdType="pubmed">19139406</ArticleId></ArticleIdList></Reference><Reference><Citation>Weitzman M.D., Weitzman J.B. What&#x2019;s the damage? The impact of pathogens on pathways that maintain host genome integrity. Cell Host Microbe. 2014;15:283&#x2013;294. doi: 10.1016/j.chom.2014.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2014.02.010</ArticleId><ArticleId IdType="pmc">PMC4501477</ArticleId><ArticleId IdType="pubmed">24629335</ArticleId></ArticleIdList></Reference><Reference><Citation>Desfarges S., Ciuffi A. Viral Integration and Consequences on Host Gene Expression. In: Witzany G., editor. Viruses: Essential Agents of Life. Springer; Dordrecht, The Netherlands: 2012. pp. 147&#x2013;175.</Citation></Reference><Reference><Citation>Soliman S.H.A., Orlacchio A., Verginelli F. Viral Manipulation of the Host Epigenome as a Driver of Virus-Induced Oncogenesis. Microorganisms. 2021;9:1179. doi: 10.3390/microorganisms9061179.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9061179</ArticleId><ArticleId IdType="pmc">PMC8227491</ArticleId><ArticleId IdType="pubmed">34070716</ArticleId></ArticleIdList></Reference><Reference><Citation>Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883&#x2013;899. doi: 10.1016/j.cell.2010.01.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.01.025</ArticleId><ArticleId IdType="pmc">PMC2866629</ArticleId><ArticleId IdType="pubmed">20303878</ArticleId></ArticleIdList></Reference><Reference><Citation>Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis. 2009;30:1073&#x2013;1081. doi: 10.1093/carcin/bgp127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/carcin/bgp127</ArticleId><ArticleId IdType="pubmed">19468060</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature. 2008;454:436&#x2013;444. doi: 10.1038/nature07205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07205</ArticleId><ArticleId IdType="pubmed">18650914</ArticleId></ArticleIdList></Reference><Reference><Citation>Balkwill F., Mantovani A. Inflammation and cancer: Back to Virchow? Lancet. 2001;357:539&#x2013;545. doi: 10.1016/S0140-6736(00)04046-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(00)04046-0</ArticleId><ArticleId IdType="pubmed">11229684</ArticleId></ArticleIdList></Reference><Reference><Citation>Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454:428&#x2013;435. doi: 10.1038/nature07201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07201</ArticleId><ArticleId IdType="pubmed">18650913</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan C.W., Housseau F. The &#x2018;kiss of death&#x2019; by dendritic cells to cancer cells. Cell Death Differ. 2008;15:58&#x2013;69. doi: 10.1038/sj.cdd.4402235.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.cdd.4402235</ArticleId><ArticleId IdType="pubmed">17948029</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H., Wu L., Yan G., Chen Y., Zhou M., Wu Y., Li Y. Inflammation and tumor progression: Signaling pathways and targeted intervention. Signal Transduct. Target. Ther. 2021;6:263. doi: 10.1038/s41392-021-00658-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00658-5</ArticleId><ArticleId IdType="pmc">PMC8273155</ArticleId><ArticleId IdType="pubmed">34248142</ArticleId></ArticleIdList></Reference><Reference><Citation>Greten F.R., Grivennikov S.I. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51:27&#x2013;41. doi: 10.1016/j.immuni.2019.06.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.06.025</ArticleId><ArticleId IdType="pmc">PMC6831096</ArticleId><ArticleId IdType="pubmed">31315034</ArticleId></ArticleIdList></Reference><Reference><Citation>DeVito N.C., Plebanek M.P., Theivanthiran B., Hanks B.A. Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion. Front. Immunol. 2019;10:2876. doi: 10.3389/fimmu.2019.02876.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02876</ArticleId><ArticleId IdType="pmc">PMC6914818</ArticleId><ArticleId IdType="pubmed">31921140</ArticleId></ArticleIdList></Reference><Reference><Citation>Coussens L.M., Werb Z. Inflammation and cancer. Nature. 2002;420:860&#x2013;867. doi: 10.1038/nature01322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01322</ArticleId><ArticleId IdType="pmc">PMC2803035</ArticleId><ArticleId IdType="pubmed">12490959</ArticleId></ArticleIdList></Reference><Reference><Citation>Piotrowski I., Kulcenty K., Suchorska W. Interplay between inflammation and cancer. Rep. Pract. Oncol. Radiother. 2020;25:422&#x2013;427. doi: 10.1016/j.rpor.2020.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rpor.2020.04.004</ArticleId><ArticleId IdType="pmc">PMC7191124</ArticleId><ArticleId IdType="pubmed">32372882</ArticleId></ArticleIdList></Reference><Reference><Citation>Prud&#x2019;homme G.J. Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab. Investig. 2007;87:1077&#x2013;1091. doi: 10.1038/labinvest.3700669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/labinvest.3700669</ArticleId><ArticleId IdType="pubmed">17724448</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Huang J., Ren X., Gorska A.E., Chytil A., Aakre M., Carbone D.P., Matrisian L.M., Richmond A., Lin P.C., et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell. 2008;13:23&#x2013;35. doi: 10.1016/j.ccr.2007.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccr.2007.12.004</ArticleId><ArticleId IdType="pmc">PMC2245859</ArticleId><ArticleId IdType="pubmed">18167337</ArticleId></ArticleIdList></Reference><Reference><Citation>Massagu&#xe9; J. TGFbeta in Cancer. Cell. 2008;134:215&#x2013;230. doi: 10.1016/j.cell.2008.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2008.07.001</ArticleId><ArticleId IdType="pmc">PMC3512574</ArticleId><ArticleId IdType="pubmed">18662538</ArticleId></ArticleIdList></Reference><Reference><Citation>Wajant H. The role of TNF in cancer. Results Probl. Cell Differ. 2009;49:1&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">19137269</ArticleId></ArticleIdList></Reference><Reference><Citation>Grivennikov S.I., Karin M. Inflammatory cytokines in cancer: Tumour necrosis factor and interleukin 6 take the stage. Ann. Rheum. Dis. 2011;70:i104&#x2013;i108. doi: 10.1136/ard.2010.140145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.140145</ArticleId><ArticleId IdType="pubmed">21339211</ArticleId></ArticleIdList></Reference><Reference><Citation>Balkwill F. Tumour necrosis factor and cancer. Nat. Rev. Cancer. 2009;9:361&#x2013;371. doi: 10.1038/nrc2628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc2628</ArticleId><ArticleId IdType="pubmed">19343034</ArticleId></ArticleIdList></Reference><Reference><Citation>Briukhovetska D., D&#xf6;rr J., Endres S., Libby P., Dinarello C.A., Kobold S. Interleukins in cancer: From biology to therapy. Nat. Rev. Cancer. 2021;21:481&#x2013;499. doi: 10.1038/s41568-021-00363-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41568-021-00363-z</ArticleId><ArticleId IdType="pmc">PMC8173513</ArticleId><ArticleId IdType="pubmed">34083781</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A., Dinarello C.A., Molgora M., Garlanda C. Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity. Immunity. 2019;50:778&#x2013;795. doi: 10.1016/j.immuni.2019.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.03.012</ArticleId><ArticleId IdType="pmc">PMC7174020</ArticleId><ArticleId IdType="pubmed">30995499</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamkanfi M., Dixit V.M. Mechanisms and functions of inflammasomes. Cell. 2014;157:1013&#x2013;1022. doi: 10.1016/j.cell.2014.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.04.007</ArticleId><ArticleId IdType="pubmed">24855941</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian S., Golubnitschaja O., Zhan X. Chronic inflammation: Key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles. EPMA J. 2019;10:365&#x2013;381. doi: 10.1007/s13167-019-00194-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13167-019-00194-x</ArticleId><ArticleId IdType="pmc">PMC6882964</ArticleId><ArticleId IdType="pubmed">31832112</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Cai G., Liu C., Zhao J., Gu C., Wu L., Hamilton T.A., Zhang C.J., Ko J., Zhu L., et al. IL-17R-EGFR axis links wound healing to tumorigenesis in Lrig1+ stem cells. J. Exp. Med. 2019;216:195&#x2013;214. doi: 10.1084/jem.20171849.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20171849</ArticleId><ArticleId IdType="pmc">PMC6314525</ArticleId><ArticleId IdType="pubmed">30578323</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi M.R., Sosman J.A., Zhang B. The Janus Face of IL-33 Signaling in Tumor Development and Immune Escape. Cancers. 2021;13:3281. doi: 10.3390/cancers13133281.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers13133281</ArticleId><ArticleId IdType="pmc">PMC8268428</ArticleId><ArticleId IdType="pubmed">34209038</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int. Immunol. 2021;33:127&#x2013;148. doi: 10.1093/intimm/dxaa078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxaa078</ArticleId><ArticleId IdType="pmc">PMC7799025</ArticleId><ArticleId IdType="pubmed">33337480</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari N., Dwarakanath B.S., Das A., Bhatt A.N. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37:11553&#x2013;11572. doi: 10.1007/s13277-016-5098-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13277-016-5098-7</ArticleId><ArticleId IdType="pubmed">27260630</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas S.K. Metabolic Reprogramming of Immune Cells in Cancer Progression. Immunity. 2015;43:435&#x2013;449. doi: 10.1016/j.immuni.2015.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2015.09.001</ArticleId><ArticleId IdType="pubmed">26377897</ArticleId></ArticleIdList></Reference><Reference><Citation>Tannahill G.M., Curtis A.M., Adamik J., Palsson-McDermott E.M., McGettrick A.F., Goel G., Frezza C., Bernard N.J., Kelly B., Foley N.H., et al. Succinate is an inflammatory signal that induces IL-1&#x3b2; through HIF-1&#x3b1;. Nature. 2013;496:238&#x2013;242. doi: 10.1038/nature11986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature11986</ArticleId><ArticleId IdType="pmc">PMC4031686</ArticleId><ArticleId IdType="pubmed">23535595</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Donnell J.S., Teng M.W.L., Smyth M.J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat. Rev. Clin. Oncol. 2019;16:151&#x2013;167. doi: 10.1038/s41571-018-0142-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41571-018-0142-8</ArticleId><ArticleId IdType="pubmed">30523282</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: Integrating immunity&#x2019;s roles in cancer suppression and promotion. Science. 2011;331:1565&#x2013;1570. doi: 10.1126/science.1203486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1203486</ArticleId><ArticleId IdType="pubmed">21436444</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn G.P., Old L.J., Schreiber R.D. The three es of cancer immunoediting. Annu. Rev. Immunol. 2004;22:329&#x2013;360. doi: 10.1146/annurev.immunol.22.012703.104803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.22.012703.104803</ArticleId><ArticleId IdType="pubmed">15032581</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C.F., Lin C.M., Lee K.Y., Wu S.Y., Feng P.H., Chen K.Y., Chuang H.C., Chen C.L., Wang Y.C., Tseng P.C., et al. Escape from IFN-&#x3b3;-dependent immunosurveillance in tumorigenesis. J. Biomed. Sci. 2017;24:10. doi: 10.1186/s12929-017-0317-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-017-0317-0</ArticleId><ArticleId IdType="pmc">PMC5286687</ArticleId><ArticleId IdType="pubmed">28143527</ArticleId></ArticleIdList></Reference><Reference><Citation>Zitvogel L., Tesniere A., Kroemer G. Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat. Rev. Immunol. 2006;6:715&#x2013;727. doi: 10.1038/nri1936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1936</ArticleId><ArticleId IdType="pubmed">16977338</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.K., Cho S.W. The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. Front. Pharmacol. 2022;13:868695. doi: 10.3389/fphar.2022.868695.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.868695</ArticleId><ArticleId IdType="pmc">PMC9171538</ArticleId><ArticleId IdType="pubmed">35685630</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty G.L., Gladney W.L. Immune escape mechanisms as a guide for cancer immunotherapy. Clin. Cancer Res. 2015;21:687&#x2013;692. doi: 10.1158/1078-0432.CCR-14-1860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-14-1860</ArticleId><ArticleId IdType="pmc">PMC4334715</ArticleId><ArticleId IdType="pubmed">25501578</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinay D.S., Ryan E.P., Pawelec G., Talib W.H., Stagg J., Elkord E., Lichtor T., Decker W.K., Whelan R.L., Kumara H.M., et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin. Cancer Biol. 2015;35:S185&#x2013;S198. doi: 10.1016/j.semcancer.2015.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semcancer.2015.03.004</ArticleId><ArticleId IdType="pubmed">25818339</ArticleId></ArticleIdList></Reference><Reference><Citation>So T., Takenoyama M., Mizukami M., Ichiki Y., Sugaya M., Hanagiri T., Sugio K., Yasumoto K. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer. Cancer Res. 2005;65:5945&#x2013;5952. doi: 10.1158/0008-5472.CAN-04-3787.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/0008-5472.CAN-04-3787</ArticleId><ArticleId IdType="pubmed">15994973</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkins D., Breuckmann A., Schmahl G.E., Binner P., Ferrone S., Krummenauer F., St&#xf6;rkel S., Seliger B. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int. J. Cancer. 2004;109:265&#x2013;273. doi: 10.1002/ijc.11681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ijc.11681</ArticleId><ArticleId IdType="pubmed">14750179</ArticleId></ArticleIdList></Reference><Reference><Citation>Ochsenbein A.F. Immunological ignorance of solid tumors. Semin. Immunopathol. 2005;27:19&#x2013;35. doi: 10.1007/s00281-004-0192-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-004-0192-0</ArticleId><ArticleId IdType="pubmed">15965711</ArticleId></ArticleIdList></Reference><Reference><Citation>Medema J.P., de Jong J., Peltenburg L.T., Verdegaal E.M., Gorter A., Bres S.A., Franken K.L., Hahne M., Albar J.P., Melief C.J., et al. Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc. Natl. Acad. Sci. USA. 2001;98:11515&#x2013;11520. doi: 10.1073/pnas.201398198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.201398198</ArticleId><ArticleId IdType="pmc">PMC58761</ArticleId><ArticleId IdType="pubmed">11562487</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronte V., Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 2005;5:641&#x2013;654. doi: 10.1038/nri1668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1668</ArticleId><ArticleId IdType="pubmed">16056256</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu A.A., Drake V., Huang H.S., Chiu S., Zheng L. Reprogramming the tumor microenvironment: Tumor-induced immunosuppressive factors paralyze T cells. Oncoimmunology. 2015;4:e1016700. doi: 10.1080/2162402X.2015.1016700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/2162402X.2015.1016700</ArticleId><ArticleId IdType="pmc">PMC4485788</ArticleId><ArticleId IdType="pubmed">26140242</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C.R., Mahdi R.M., Ebong S., Vistica B.P., Gery I., Egwuagu C.E. Suppressor of cytokine signaling 3 regulates proliferation and activation of T-helper cells. J. Biol. Chem. 2003;278:29752&#x2013;29759. doi: 10.1074/jbc.M300489200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M300489200</ArticleId><ArticleId IdType="pubmed">12783879</ArticleId></ArticleIdList></Reference><Reference><Citation>Egwuagu C.E., Yu C.R., Zhang M., Mahdi R.M., Kim S.J., Gery I. Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: Implications for Th cell lineage commitment and maintenance. J. Immunol. 2002;168:3181&#x2013;3187. doi: 10.4049/jimmunol.168.7.3181.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.168.7.3181</ArticleId><ArticleId IdType="pubmed">11907070</ArticleId></ArticleIdList></Reference><Reference><Citation>Wherry E.J., Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 2015;15:486&#x2013;499. doi: 10.1038/nri3862.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3862</ArticleId><ArticleId IdType="pmc">PMC4889009</ArticleId><ArticleId IdType="pubmed">26205583</ArticleId></ArticleIdList></Reference><Reference><Citation>Pauken K.E., Wherry E.J. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36:265&#x2013;276. doi: 10.1016/j.it.2015.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2015.02.008</ArticleId><ArticleId IdType="pmc">PMC4393798</ArticleId><ArticleId IdType="pubmed">25797516</ArticleId></ArticleIdList></Reference><Reference><Citation>Uyttenhove C., Pilotte L., Th&#xe9;ate I., Stroobant V., Colau D., Parmentier N., Boon T., Van den Eynde B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003;9:1269&#x2013;1274. doi: 10.1038/nm934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm934</ArticleId><ArticleId IdType="pubmed">14502282</ArticleId></ArticleIdList></Reference><Reference><Citation>Terness P., Bauer T.M., R&#xf6;se L., Dufter C., Watzlik A., Simon H., Opelz G. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: Mediation of suppression by tryptophan metabolites. J. Exp. Med. 2002;196:447&#x2013;457. doi: 10.1084/jem.20020052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20020052</ArticleId><ArticleId IdType="pmc">PMC2196057</ArticleId><ArticleId IdType="pubmed">12186837</ArticleId></ArticleIdList></Reference><Reference><Citation>Allavena P., Sica A., Solinas G., Porta C., Mantovani A. The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages. Crit. Rev. Oncol. Hematol. 2008;66:1&#x2013;9. doi: 10.1016/j.critrevonc.2007.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2007.07.004</ArticleId><ArticleId IdType="pubmed">17913510</ArticleId></ArticleIdList></Reference><Reference><Citation>Khaled Y.S., Ammori B.J., Elkord E. Myeloid-derived suppressor cells in cancer: Recent progress and prospects. Immunol. Cell Biol. 2013;91:493&#x2013;502. doi: 10.1038/icb.2013.29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/icb.2013.29</ArticleId><ArticleId IdType="pubmed">23797066</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012;12:253&#x2013;268. doi: 10.1038/nri3175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3175</ArticleId><ArticleId IdType="pmc">PMC3587148</ArticleId><ArticleId IdType="pubmed">22437938</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y., Obholzer N., Fayad R., Qiao L. Turning on/off tumor-specific CTL response during progressive tumor growth. J. Immunol. 2005;175:3110&#x2013;3116. doi: 10.4049/jimmunol.175.5.3110.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.175.5.3110</ArticleId><ArticleId IdType="pubmed">16116200</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou G., Lu Z., McCadden J.D., Levitsky H.I., Marson A.L. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J. Exp. Med. 2004;200:1581&#x2013;1592. doi: 10.1084/jem.20041240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20041240</ArticleId><ArticleId IdType="pmc">PMC2211996</ArticleId><ArticleId IdType="pubmed">15596524</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004;22:531&#x2013;562. doi: 10.1146/annurev.immunol.21.120601.141122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.21.120601.141122</ArticleId><ArticleId IdType="pubmed">15032588</ArticleId></ArticleIdList></Reference><Reference><Citation>Thursby E., Juge N. Introduction to the human gut microbiota. Biochem. J. 2017;474:1823&#x2013;1836. doi: 10.1042/BCJ20160510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20160510</ArticleId><ArticleId IdType="pmc">PMC5433529</ArticleId><ArticleId IdType="pubmed">28512250</ArticleId></ArticleIdList></Reference><Reference><Citation>Durack J., Lynch S.V. The gut microbiome: Relationships with disease and opportunities for therapy. J. Exp. Med. 2019;216:20&#x2013;40. doi: 10.1084/jem.20180448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20180448</ArticleId><ArticleId IdType="pmc">PMC6314516</ArticleId><ArticleId IdType="pubmed">30322864</ArticleId></ArticleIdList></Reference><Reference><Citation>Jandhyala S.M., Talukdar R., Subramanyam C., Vuyyuru H., Sasikala M., Nageshwar Reddy D. Role of the normal gut microbiota. World J. Gastroenterol. 2015;21:8787&#x2013;8803. doi: 10.3748/wjg.v21.i29.8787.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v21.i29.8787</ArticleId><ArticleId IdType="pmc">PMC4528021</ArticleId><ArticleId IdType="pubmed">26269668</ArticleId></ArticleIdList></Reference><Reference><Citation>Carding S., Verbeke K., Vipond D.T., Corfe B.M., Owen L.J. Dysbiosis of the gut microbiota in disease. Microb. Ecol. Health Dis. 2015;26:26191. doi: 10.3402/mehd.v26.26191.</Citation><ArticleIdList><ArticleId IdType="doi">10.3402/mehd.v26.26191</ArticleId><ArticleId IdType="pmc">PMC4315779</ArticleId><ArticleId IdType="pubmed">25651997</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y., Pedersen O. Gut microbiota in human metabolic health and disease. Nat. Rev. Microbiol. 2021;19:55&#x2013;71. doi: 10.1038/s41579-020-0433-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-0433-9</ArticleId><ArticleId IdType="pubmed">32887946</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulbright L.E., Ellermann M., Arthur J.C. The microbiome and the hallmarks of cancer. PLoS Pathog. 2017;13:e1006480. doi: 10.1371/journal.ppat.1006480.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1006480</ArticleId><ArticleId IdType="pmc">PMC5608396</ArticleId><ArticleId IdType="pubmed">28934351</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagnaire A., Nadel B., Raoult D., Neefjes J., Gorvel J.P. Collateral damage: Insights into bacterial mechanisms that predispose host cells to cancer. Nat. Rev. Microbiol. 2017;15:109&#x2013;128. doi: 10.1038/nrmicro.2016.171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro.2016.171</ArticleId><ArticleId IdType="pubmed">28045107</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivarelli S., Salemi R., Candido S., Falzone L., Santagati M., Stefani S., Torino F., Banna G.L., Tonini G., Libra M. Gut Microbiota and Cancer: From Pathogenesis to Therapy. Cancers. 2019;11:38. doi: 10.3390/cancers11010038.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers11010038</ArticleId><ArticleId IdType="pmc">PMC6356461</ArticleId><ArticleId IdType="pubmed">30609850</ArticleId></ArticleIdList></Reference><Reference><Citation>Zitvogel L., Daill&#xe8;re R., Roberti M.P., Routy B., Kroemer G. Anticancer effects of the microbiome and its products. Nat. Rev. Microbiol. 2017;15:465&#x2013;478. doi: 10.1038/nrmicro.2017.44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro.2017.44</ArticleId><ArticleId IdType="pubmed">28529325</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge Y., Wang X., Guo Y., Yan J., Abuduwaili A., Aximujiang K., Yan J., Wu M. Gut microbiota influence tumor development and Alter interactions with the human immune system. J. Exp. Clin. Cancer Res. 2021;40:42. doi: 10.1186/s13046-021-01845-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13046-021-01845-6</ArticleId><ArticleId IdType="pmc">PMC7829621</ArticleId><ArticleId IdType="pubmed">33494784</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt A.P., Redinbo M.R., Bultman S.J. The role of the microbiome in cancer development and therapy. CA Cancer J. Clin. 2017;67:326&#x2013;344. doi: 10.3322/caac.21398.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21398</ArticleId><ArticleId IdType="pmc">PMC5530583</ArticleId><ArticleId IdType="pubmed">28481406</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiorentini C., Carlini F., Germinario E.A.P., Maroccia Z., Travaglione S., Fabbri A. Gut Microbiota and Colon Cancer: A Role for Bacterial Protein Toxins? Int. J. Mol. Sci. 2020;21:6201. doi: 10.3390/ijms21176201.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21176201</ArticleId><ArticleId IdType="pmc">PMC7504354</ArticleId><ArticleId IdType="pubmed">32867331</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisan T. Bacterial genotoxins: The long journey to the nucleus of mammalian cells. Biochim. Biophys. Acta. 2016;1858:567&#x2013;575. doi: 10.1016/j.bbamem.2015.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamem.2015.08.016</ArticleId><ArticleId IdType="pubmed">26299818</ArticleId></ArticleIdList></Reference><Reference><Citation>Lara-Tejero M., Gal&#xe1;n J.E. A bacterial toxin that controls cell cycle progression as a deoxyribonuclease I-like protein. Science. 2000;290:354&#x2013;357. doi: 10.1126/science.290.5490.354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.290.5490.354</ArticleId><ArticleId IdType="pubmed">11030657</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Y., Dai W. Genomic Instability and Cancer. J. Carcinog. Mutagen. 2014;5:1000165.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4274643</ArticleId><ArticleId IdType="pubmed">25541596</ArticleId></ArticleIdList></Reference><Reference><Citation>Wada Y., Takemura K., Tummala P., Uchida K., Kitagaki K., Furukawa A., Ishige Y., Ito T., Hara Y., Suzuki T., et al. Helicobacter pylori induces somatic mutations in TP53 via overexpression of CHAC1 in infected gastric epithelial cells. FEBS Open Bio. 2018;8:671&#x2013;679. doi: 10.1002/2211-5463.12402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/2211-5463.12402</ArticleId><ArticleId IdType="pmc">PMC5881537</ArticleId><ArticleId IdType="pubmed">29632819</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergounioux J., Elisee R., Prunier A.L., Donnadieu F., Sperandio B., Sansonetti P., Arbibe L. Calpain activation by the Shigella flexneri effector VirA regulates key steps in the formation and life of the bacterium&#x2019;s epithelial niche. Cell Host Microbe. 2012;11:240&#x2013;252. doi: 10.1016/j.chom.2012.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2012.01.013</ArticleId><ArticleId IdType="pubmed">22423964</ArticleId></ArticleIdList></Reference><Reference><Citation>Buti L., Spooner E., Van der Veen A.G., Rappuoli R., Covacci A., Ploegh H.L. Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host. Proc. Natl. Acad. Sci. USA. 2011;108:9238&#x2013;9243. doi: 10.1073/pnas.1106200108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1106200108</ArticleId><ArticleId IdType="pmc">PMC3107298</ArticleId><ArticleId IdType="pubmed">21562218</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaturvedi R., Asim M., Romero-Gallo J., Barry D.P., Hoge S., de Sablet T., Delgado A.G., Wroblewski L.E., Piazuelo M.B., Yan F., et al. Spermine oxidase mediates the gastric cancer risk associated with Helicobacter pylori CagA. Gastroenterology. 2011;141:1696&#x2013;1708. doi: 10.1053/j.gastro.2011.07.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2011.07.045</ArticleId><ArticleId IdType="pmc">PMC3202654</ArticleId><ArticleId IdType="pubmed">21839041</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodwin A.C., Destefano Shields C.E., Wu S., Huso D.L., Wu X., Murray-Stewart T.R., Hacker-Prietz A., Rabizadeh S., Woster P.M., Sears C.L., et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc. Natl. Acad. Sci. USA. 2011;108:15354&#x2013;15359. doi: 10.1073/pnas.1010203108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1010203108</ArticleId><ArticleId IdType="pmc">PMC3174648</ArticleId><ArticleId IdType="pubmed">21876161</ArticleId></ArticleIdList></Reference><Reference><Citation>Belkaid Y., Hand T.W. Role of the microbiota in immunity and inflammation. Cell. 2014;157:121&#x2013;141. doi: 10.1016/j.cell.2014.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.03.011</ArticleId><ArticleId IdType="pmc">PMC4056765</ArticleId><ArticleId IdType="pubmed">24679531</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Elinav E., Huber S., Strowig T., Hao L., Hafemann A., Jin C., Wunderlich C., Wunderlich T., Eisenbarth S.C., et al. Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer. Proc. Natl. Acad. Sci. USA. 2013;110:9862&#x2013;9867. doi: 10.1073/pnas.1307575110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1307575110</ArticleId><ArticleId IdType="pmc">PMC3683709</ArticleId><ArticleId IdType="pubmed">23696660</ArticleId></ArticleIdList></Reference><Reference><Citation>Caesar R., Tremaroli V., Kovatcheva-Datchary P., Cani P.D., Backhed F. Crosstalk between gut microbiota and dietary lipids aggravates WAT inflammation through TLR signaling. Cell Metab. 2015;22:658&#x2013;668. doi: 10.1016/j.cmet.2015.07.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2015.07.026</ArticleId><ArticleId IdType="pmc">PMC4598654</ArticleId><ArticleId IdType="pubmed">26321659</ArticleId></ArticleIdList></Reference><Reference><Citation>Gur C., Ibrahim Y., Isaacson B., Yamin R., Abed J., Gamliel M., Enk J., Bar-On Y., Stanietsky-Kaynan N., Coppenhagen-Glazer S., et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42:344&#x2013;355. doi: 10.1016/j.immuni.2015.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2015.01.010</ArticleId><ArticleId IdType="pmc">PMC4361732</ArticleId><ArticleId IdType="pubmed">25680274</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S.H., Minn D., Kim S.W., Kim Y.K. Inflammatory Markers and Cytokines in Moderate and Critical Cases of COVID-19. Clin. Lab. 2021;67 doi: 10.7754/Clin.Lab.2021.210142.</Citation><ArticleIdList><ArticleId IdType="doi">10.7754/Clin.Lab.2021.210142</ArticleId><ArticleId IdType="pubmed">34542974</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F., Cao J., Yu Y., Ding J., Eshak E.S., Liu K., Mubarik S., Shi F., Wen H., Zeng Z., et al. Epidemiological characteristics of patients with severe COVID-19 infection in Wuhan, China: Evidence from a retrospective observational study. Int. J. Epidemiol. 2021;49:1940&#x2013;1950. doi: 10.1093/ije/dyaa180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyaa180</ArticleId><ArticleId IdType="pmc">PMC7665537</ArticleId><ArticleId IdType="pubmed">33150437</ArticleId></ArticleIdList></Reference><Reference><Citation>da Silva Torres M.K., Bichara C.D.A., de Almeida M., Vallinoto M.C., Queiroz M.A.F., Vallinoto I., Dos Santos E.J.M., de Carvalho C.A.M., Vallinoto A.C.R. The Complexity of SARS-CoV-2 Infection and the COVID-19 Pandemic. Front. Microbiol. 2022;13:789882. doi: 10.3389/fmicb.2022.789882.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.789882</ArticleId><ArticleId IdType="pmc">PMC8870622</ArticleId><ArticleId IdType="pubmed">35222327</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur S., Bansal R., Kollimuttathuillam S., Gowda A.M., Singh B., Mehta D., Maroules M. The looming storm: Blood and cytokines in COVID-19. Blood Rev. 2021;46:100743. doi: 10.1016/j.blre.2020.100743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2020.100743</ArticleId><ArticleId IdType="pmc">PMC7431319</ArticleId><ArticleId IdType="pubmed">32829962</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Klein S.L., Garibaldi B.T., Li H., Wu C., Osevala N.M., Li T., Margolick J.B., Pawelec G., Leng S.X. Aging in COVID-19: Vulnerability, immunity and intervention. Ageing Res. Rev. 2021;65:101205. doi: 10.1016/j.arr.2020.101205.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2020.101205</ArticleId><ArticleId IdType="pmc">PMC7604159</ArticleId><ArticleId IdType="pubmed">33137510</ArticleId></ArticleIdList></Reference><Reference><Citation>Java A., Apicelli A.J., Liszewski M.K., Coler-Reilly A., Atkinson J.P., Kim A.H., Kulkarni H.S. The complement system in COVID-19: Friend and foe? JCI Insight. 2020;5:e140711. doi: 10.1172/jci.insight.140711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.140711</ArticleId><ArticleId IdType="pmc">PMC7455060</ArticleId><ArticleId IdType="pubmed">32554923</ArticleId></ArticleIdList></Reference><Reference><Citation>Teijaro J.R. Cytokine storms in infectious diseases. Semin. Immunopathol. 2017;39:501&#x2013;503. doi: 10.1007/s00281-017-0640-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-017-0640-2</ArticleId><ArticleId IdType="pmc">PMC7079934</ArticleId><ArticleId IdType="pubmed">28674818</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L.Y.C., Quach T.T.T. COVID-19 cytokine storm syndrome: A threshold concept. Lancet Microbe. 2021;2:e49&#x2013;e50. doi: 10.1016/S2666-5247(20)30223-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30223-8</ArticleId><ArticleId IdType="pmc">PMC7906728</ArticleId><ArticleId IdType="pubmed">33655230</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497&#x2013;506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kunnumakkara A.B., Rana V., Parama D., Banik K., Girisa S., Henamayee S., Thakur K.K., Dutta U., Garodia P., Gupta S.C., et al. COVID-19, cytokines, inflammation, and spices: How are they related? Life Sci. 2021;284:119201. doi: 10.1016/j.lfs.2021.119201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2021.119201</ArticleId><ArticleId IdType="pmc">PMC7884924</ArticleId><ArticleId IdType="pubmed">33607159</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos-Bourboulis E.J., Netea M.G., Rovina N., Akinosoglou K., Antoniadou A., Antonakos N., Damoraki G., Gkavogianni T., Adami M.E., Katsaounou P., et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe. 2020;27:992&#x2013;1000.e3. doi: 10.1016/j.chom.2020.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.009</ArticleId><ArticleId IdType="pmc">PMC7172841</ArticleId><ArticleId IdType="pubmed">32320677</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue J.K., Franko N.M., McCulloch D.J., McDonald D., Magedson A., Wolf C.R., Chu H.Y. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw. Open. 2021;4:e210830. doi: 10.1001/jamanetworkopen.2021.0830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0830</ArticleId><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z., Xie Y., Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594:259&#x2013;264. doi: 10.1038/s41586-021-03553-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., Liu M., Zhou X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Montefusco L., Ben Nasr M., D&#x2019;Addio F., Loretelli C., Rossi A., Pastore I., Daniele G., Abdelsalam A., Maestroni A., Dell&#x2019;Acqua M., et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat. Metab. 2021;3:774&#x2013;785. doi: 10.1038/s42255-021-00407-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42255-021-00407-6</ArticleId><ArticleId IdType="pmc">PMC9931026</ArticleId><ArticleId IdType="pubmed">34035524</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwala P., Salzman S.H. Six-Minute Walk Test: Clinical Role, Technique, Coding, and Reimbursement. Chest. 2020;157:603&#x2013;611. doi: 10.1016/j.chest.2019.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2019.10.014</ArticleId><ArticleId IdType="pmc">PMC7609960</ArticleId><ArticleId IdType="pubmed">31689414</ArticleId></ArticleIdList></Reference><Reference><Citation>Blomberg B., Mohn K.G., Brokstad K.A., Zhou F., Linchausen D.W., Hansen B.A., Lartey S., Onyango T.B., Kuwelker K., Saevik M., et al. Long COVID in a prospective cohort of home-isolated patients. Nat. Med. 2021;27:1607&#x2013;1613. doi: 10.1038/s41591-021-01433-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01433-3</ArticleId><ArticleId IdType="pmc">PMC8440190</ArticleId><ArticleId IdType="pubmed">34163090</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Parums D.V. Editorial: Long COVID, or Post-COVID Syndrome, and the Global Impact on Health Care. Med. Sci. Monit. 2021;27:e933446. doi: 10.12659/MSM.933446.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.933446</ArticleId><ArticleId IdType="pmc">PMC8194290</ArticleId><ArticleId IdType="pubmed">34092779</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykes D.L., Holdsworth L., Jawad N., Gunasekera P., Morice A.H., Crooks M.G. Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It? Lung. 2021;199:113&#x2013;119. doi: 10.1007/s00408-021-00423-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00408-021-00423-z</ArticleId><ArticleId IdType="pmc">PMC7875681</ArticleId><ArticleId IdType="pubmed">33569660</ArticleId></ArticleIdList></Reference><Reference><Citation>Naeije R., Caravita S. Phenotyping long COVID. Eur. Respir. J. 2021;58:2101763. doi: 10.1183/13993003.01763-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01763-2021</ArticleId><ArticleId IdType="pmc">PMC8287735</ArticleId><ArticleId IdType="pubmed">34244323</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D., VanElzakker M.B. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front. Microbiol. 2021;12:698169. doi: 10.3389/fmicb.2021.698169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiroz M.A.F., Neves P., Lima S.S., Lopes J.D.C., Torres M., Vallinoto I., Bichara C.D.A., Dos Santos E.F., de Brito M., da Silva A.L.S., et al. Cytokine Profiles Associated With Acute COVID-19 and Long COVID-19 Syndrome. Front. Cell Infect. Microbiol. 2022;12:922422. doi: 10.3389/fcimb.2022.922422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.922422</ArticleId><ArticleId IdType="pmc">PMC9279918</ArticleId><ArticleId IdType="pubmed">35846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno-Perez O., Merino E., Leon-Ramirez J.M., Andres M., Ramos J.M., Arenas-Jimenez J., Asensio S., Sanchez R., Ruiz-Torregrosa P., Galan I., et al. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. J. Infect. 2021;82:378&#x2013;383. doi: 10.1016/j.jinf.2021.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.01.004</ArticleId><ArticleId IdType="pmc">PMC7802523</ArticleId><ArticleId IdType="pubmed">33450302</ArticleId></ArticleIdList></Reference><Reference><Citation>Sapir T., Averch Z., Lerman B., Bodzin A., Fishman Y., Maitra R. COVID-19 and the Immune Response: A Multi-Phasic Approach to the Treatment of COVID-19. Int. J. Mol. Sci. 2022;23:8606. doi: 10.3390/ijms23158606.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23158606</ArticleId><ArticleId IdType="pmc">PMC9369212</ArticleId><ArticleId IdType="pubmed">35955740</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechner-Scott J., Levy M., Hawkes C., Yeh A., Giovannoni G. Long COVID or post COVID-19 syndrome. Mult. Scler. Relat. Dis. 2021;55:103268. doi: 10.1016/j.msard.2021.103268.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2021.103268</ArticleId><ArticleId IdType="pmc">PMC8447548</ArticleId><ArticleId IdType="pubmed">34601388</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C., Willscher E., Paschold L., Gottschick C., Klee B., Henkes S.S., Bosurgi L., Dutzmann J., Sedding D., Frese T., et al. The IL-1&#x3b2;, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep. Med. 2022;3:100663. doi: 10.1016/j.xcrm.2022.100663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100663</ArticleId><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Lu S., Tang A.F., Durstenfeld M.S., Ho H.E., Goldberg S.A., Forman C.A., Munter S.E., Hoh R., Tai V., et al. Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J. Infect. Dis. 2021;224:1839&#x2013;1848. doi: 10.1093/infdis/jiab490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Ampudia Y., Monsalve D.M., Rojas M., Rodr&#xed;guez Y., Zapata E., Ram&#xed;rez-Santana C., Anaya J.M. Persistent Autoimmune Activation and Proinflammatory State in Post-Coronavirus Disease 2019 Syndrome. J. Infect. Dis. 2022;225:2155&#x2013;2162. doi: 10.1093/infdis/jiac017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac017</ArticleId><ArticleId IdType="pmc">PMC8903340</ArticleId><ArticleId IdType="pubmed">35079804</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C., Darley D.R., Wilson D.B., Howe A., Munier C.M.L., Patel S.K., Juno J.A., Burrell L.M., Kent S.J., Dore G.J., et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 2022;23:210&#x2013;216. doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Sette A., Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861&#x2013;880. doi: 10.1016/j.cell.2021.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.007</ArticleId><ArticleId IdType="pmc">PMC7803150</ArticleId><ArticleId IdType="pubmed">33497610</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam P.S., Wimmers F., Mok C.K.P., Perera R., Scott M., Hagan T., Sigal N., Feng Y., Bristow L., Tak-Yin Tsang O., et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science. 2020;369:1210&#x2013;1220. doi: 10.1126/science.abc6261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6261</ArticleId><ArticleId IdType="pmc">PMC7665312</ArticleId><ArticleId IdType="pubmed">32788292</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Rosen L.B., Zhang Q., Michailidis E., Hoffmann H.H., Zhang Y., Dorgham K., Philippot Q., Rosain J., Beziat V., et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585. doi: 10.1126/science.abd4585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D., Nilsson-Payant B.E., Liu W.C., Uhl S., Hoagland D., Moller R., Jordan T.X., Oishi K., Panis M., Sachs D., et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181:1036&#x2013;1045.e9. doi: 10.1016/j.cell.2020.04.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.04.026</ArticleId><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Laing A.G., Lorenc A., Del Molino Del Barrio I., Das A., Fish M., Monin L., Munoz-Ruiz M., McKenzie D.R., Hayday T.S., Francos-Quijorna I., et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat. Med. 2020;26:1623&#x2013;1635. doi: 10.1038/s41591-020-1038-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1038-6</ArticleId><ArticleId IdType="pubmed">32807934</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S., Jiang L., Li X., Lin F., Wang Y., Li B., Jiang T., An W., Liu S., Liu H., et al. Clinical and pathological investigation of patients with severe COVID-19. JCI Insight. 2020;5:e138070. doi: 10.1172/jci.insight.138070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.138070</ArticleId><ArticleId IdType="pmc">PMC7406259</ArticleId><ArticleId IdType="pubmed">32427582</ArticleId></ArticleIdList></Reference><Reference><Citation>Schurink B., Roos E., Radonic T., Barbe E., Bouman C.S.C., de Boer H.H., de Bree G.J., Bulle E.B., Aronica E.M., Florquin S., et al. Viral presence and immunopathology in patients with lethal COVID-19: A prospective autopsy cohort study. Lancet Microbe. 2020;1:e290&#x2013;e299. doi: 10.1016/S2666-5247(20)30144-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30144-0</ArticleId><ArticleId IdType="pmc">PMC7518879</ArticleId><ArticleId IdType="pubmed">33015653</ArticleId></ArticleIdList></Reference><Reference><Citation>Magleby R., Westblade L.F., Trzebucki A., Simon M.S., Rajan M., Park J., Goyal P., Safford M.M., Satlin M.J. Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With Coronavirus Disease 2019. Clin. Infect. Dis. 2021;73:e4197&#x2013;e4205. doi: 10.1093/cid/ciaa851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa851</ArticleId><ArticleId IdType="pmc">PMC7337625</ArticleId><ArticleId IdType="pubmed">32603425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuri-Cervantes L., Pampena M.B., Meng W., Rosenfeld A.M., Ittner C.A.G., Weisman A.R., Agyekum R.S., Mathew D., Baxter A.E., Vella L.A., et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci. Immunol. 2020;5:eabd7114. doi: 10.1126/sciimmunol.abd7114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd7114</ArticleId><ArticleId IdType="pmc">PMC7402634</ArticleId><ArticleId IdType="pubmed">32669287</ArticleId></ArticleIdList></Reference><Reference><Citation>Galani I.E., Rovina N., Lampropoulou V., Triantafyllia V., Manioudaki M., Pavlos E., Koukaki E., Fragkou P.C., Panou V., Rapti V., et al. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat. Immunol. 2021;22:32&#x2013;40. doi: 10.1038/s41590-020-00840-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00840-x</ArticleId><ArticleId IdType="pubmed">33277638</ArticleId></ArticleIdList></Reference><Reference><Citation>Files J.K., Sarkar S., Fram T.R., Boppana S., Sterrett S., Qin K., Bansal A., Long D.M., Sabbaj S., Kobie J.J., et al. Duration of post-COVID-19 symptoms is associated with sustained SARS-CoV-2-specific immune responses. JCI Insight. 2021;6:e151544. doi: 10.1172/jci.insight.151544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.151544</ArticleId><ArticleId IdType="pmc">PMC8410022</ArticleId><ArticleId IdType="pubmed">34143754</ArticleId></ArticleIdList></Reference><Reference><Citation>Loretelli C., Abdelsalam A., D&#x2019;Addio F., Ben Nasr M., Assi E., Usuelli V., Maestroni A., Seelam A.J., Ippolito E., Di Maggio S., et al. PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune response. JCI Insight. 2021;6:e146701. doi: 10.1172/jci.insight.146701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.146701</ArticleId><ArticleId IdType="pmc">PMC8783674</ArticleId><ArticleId IdType="pubmed">34784300</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynne P., Tahmasebi N., Gant V., Gupta R. Long COVID following mild SARS-CoV-2 infection: Characteristic T cell alterations and response to antihistamines. J. Investig. Med. 2022;70:61&#x2013;67. doi: 10.1136/jim-2021-002051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jim-2021-002051</ArticleId><ArticleId IdType="pmc">PMC8494538</ArticleId><ArticleId IdType="pubmed">34611034</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal&#xe1;n M., Vig&#xf3;n L., Fuertes D., Murciano-Ant&#xf3;n M.A., Casado-Fern&#xe1;ndez G., Dom&#xed;nguez-Mateos S., Mateos E., Ramos-Mart&#xed;n F., Planelles V., Torres M., et al. Persistent Overactive Cytotoxic Immune Response in a Spanish Cohort of Individuals With Long-COVID: Identification of Diagnostic Biomarkers. Front. Immunol. 2022;13:848886. doi: 10.3389/fimmu.2022.848886.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.848886</ArticleId><ArticleId IdType="pmc">PMC8990790</ArticleId><ArticleId IdType="pubmed">35401523</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Deitchman A.N., Torres L., Iyer N.S., Munter S.E., Nixon C.C., Donatelli J., Thanh C., Takahashi S., Hakim J., et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 2021;36:109518. doi: 10.1016/j.celrep.2021.109518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109518</ArticleId><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiech M., Chroscicki P., Swatler J., Stepnik D., De Biasi S., Hampel M., Brewinska-Olchowik M., Maliszewska A., Sklinda K., Durlik M., et al. Remodeling of T Cell Dynamics During Long COVID Is Dependent on Severity of SARS-CoV-2 Infection. Front. Immunol. 2022;13:886431. doi: 10.3389/fimmu.2022.886431.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.886431</ArticleId><ArticleId IdType="pmc">PMC9226563</ArticleId><ArticleId IdType="pubmed">35757700</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarjour N.N., Masopust D., Jameson S.C. T cell memory: Understanding COVID-19. Immunity. 2021;54:14&#x2013;18. doi: 10.1016/j.immuni.2020.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.12.009</ArticleId><ArticleId IdType="pmc">PMC7749639</ArticleId><ArticleId IdType="pubmed">33406391</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisberg S.P., Ural B.B., Farber D.L. Tissue-specific immunity for a changing world. Cell. 2021;184:1517&#x2013;1529. doi: 10.1016/j.cell.2021.01.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.01.042</ArticleId><ArticleId IdType="pmc">PMC7988978</ArticleId><ArticleId IdType="pubmed">33740452</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasson S.C., Gordon C.L., Christo S.N., Klenerman P., Mackay L.K. Local heroes or villains: Tissue-resident memory T cells in human health and disease. Cell. Mol. Immunol. 2020;17:113&#x2013;122. doi: 10.1038/s41423-019-0359-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-019-0359-1</ArticleId><ArticleId IdType="pmc">PMC7000672</ArticleId><ArticleId IdType="pubmed">31969685</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Wang S., Goplen N.P., Li C., Cheon I.S., Dai Q., Huang S., Shan J., Ma C., Ye Z., et al. PD-1hi CD8+ resident memory T cells balance immunity and fibrotic sequelae. Sci. Immunol. 2019;4:eaaw1217. doi: 10.1126/sciimmunol.aaw1217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.aaw1217</ArticleId><ArticleId IdType="pmc">PMC7458867</ArticleId><ArticleId IdType="pubmed">31201259</ArticleId></ArticleIdList></Reference><Reference><Citation>Goplen N.P., Wu Y., Son Y.M., Li C., Wang Z., Cheon I.S., Jiang L., Zhu B., Ayasoufi K., Chini E.N., et al. Tissue-resident CD8(+) T cells drive age-associated chronic lung sequelae after viral pneumonia. Sci. Immunol. 2020;5:eabc4557. doi: 10.1126/sciimmunol.abc4557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abc4557</ArticleId><ArticleId IdType="pmc">PMC7970412</ArticleId><ArticleId IdType="pubmed">33158975</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheon I.S., Li C., Son Y.M., Goplen N.P., Wu Y., Cassmann T., Wang Z., Wei X., Tang J., Li Y., et al. Immune signatures underlying post-acute COVID-19 lung sequelae. Sci. Immunol. 2021;6:eabk1741. doi: 10.1126/sciimmunol.abk1741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abk1741</ArticleId><ArticleId IdType="pmc">PMC8763087</ArticleId><ArticleId IdType="pubmed">34591653</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Guo H., Zhou P., Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2021;19:141&#x2013;154. doi: 10.1038/s41579-020-00459-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham E.L., Janssen W.J., Riches D.W., Moss M., Downey G.P. The fibroproliferative response in acute respiratory distress syndrome: Mechanisms and clinical significance. Eur. Respir. J. 2014;43:276&#x2013;285. doi: 10.1183/09031936.00196412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.00196412</ArticleId><ArticleId IdType="pmc">PMC4015132</ArticleId><ArticleId IdType="pubmed">23520315</ArticleId></ArticleIdList></Reference><Reference><Citation>Misharin A.V., Morales-Nebreda L., Reyfman P.A., Cuda C.M., Walter J.M., McQuattie-Pimentel A.C., Chen C.I., Anekalla K.R., Joshi N., Williams K.J.N., et al. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span. J. Exp. Med. 2017;214:2387&#x2013;2404. doi: 10.1084/jem.20162152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20162152</ArticleId><ArticleId IdType="pmc">PMC5551573</ArticleId><ArticleId IdType="pubmed">28694385</ArticleId></ArticleIdList></Reference><Reference><Citation>Budinger G.R.S., Misharin A.V., Ridge K.M., Singer B.D., Wunderink R.G. Distinctive features of severe SARS-CoV-2 pneumonia. J. Clin. Investig. 2021;131:e149412. doi: 10.1172/JCI149412.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI149412</ArticleId><ArticleId IdType="pmc">PMC8279580</ArticleId><ArticleId IdType="pubmed">34263736</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xd8;stergaard L. SARS-CoV-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation. Physiol. Rep. 2021;9:e14726. doi: 10.14814/phy2.14726.</Citation><ArticleIdList><ArticleId IdType="doi">10.14814/phy2.14726</ArticleId><ArticleId IdType="pmc">PMC7849453</ArticleId><ArticleId IdType="pubmed">33523608</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Yu C., Jing H., Wu X., Novakovic V.A., Xie R., Shi J. Long COVID: The Nature of Thrombotic Sequelae Determines the Necessity of Early Anticoagulation. Front. Cell Infect. Microbiol. 2022;12:861703. doi: 10.3389/fcimb.2022.861703.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.861703</ArticleId><ArticleId IdType="pmc">PMC9016198</ArticleId><ArticleId IdType="pubmed">35449732</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Laubscher G.J., Pretorius E. A central role for amyloid fibrin microclots in long COVID/PASC: Origins and therapeutic implications. Biochem. J. 2022;479:537&#x2013;559. doi: 10.1042/BCJ20220016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20220016</ArticleId><ArticleId IdType="pmc">PMC8883497</ArticleId><ArticleId IdType="pubmed">35195253</ArticleId></ArticleIdList></Reference><Reference><Citation>Libby P., Luscher T. COVID-19 is, in the end, an endothelial disease. Eur. Heart J. 2020;41:3038&#x2013;3044. doi: 10.1093/eurheartj/ehaa623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa623</ArticleId><ArticleId IdType="pmc">PMC7470753</ArticleId><ArticleId IdType="pubmed">32882706</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong S.J. Long COVID or post-COVID-19 syndrome: Putative pathophysiology, risk factors, and treatments. Infect. Dis. 2021;53:737&#x2013;754. doi: 10.1080/23744235.2021.1924397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1924397</ArticleId><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeoh Y.K., Zuo T., Lui G.C., Zhang F., Liu Q., Li A.Y., Chung A.C., Cheung C.P., Tso E.Y., Fung K.S., et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021;70:698&#x2013;706. doi: 10.1136/gutjnl-2020-323020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-323020</ArticleId><ArticleId IdType="pmc">PMC7804842</ArticleId><ArticleId IdType="pubmed">33431578</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395:507&#x2013;513. doi: 10.1016/S0140-6736(20)30211-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30211-7</ArticleId><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W., Feng Z., Rao S., Xiao C., Xue X., Lin Z., Zhang Q., Qi W. Diarrhoea may be underestimated: A missing link in 2019 novel coronavirus. Gut. 2020;69:1141&#x2013;1143. doi: 10.1136/gutjnl-2020-320832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-320832</ArticleId><ArticleId IdType="pubmed">32102928</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfel R., Corman V.M., Guggemos W., Seilmaier M., Zange S., Muller M.A., Niemeyer D., Jones T.C., Vollmar P., Rothe C., et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465&#x2013;469. doi: 10.1038/s41586-020-2196-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2196-x</ArticleId><ArticleId IdType="pubmed">32235945</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y., Li X., Zhu B., Liang H., Fang C., Gong Y., Guo Q., Sun X., Zhao D., Shen J., et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. Nat. Med. 2020;26:502&#x2013;505. doi: 10.1038/s41591-020-0817-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0817-4</ArticleId><ArticleId IdType="pmc">PMC7095102</ArticleId><ArticleId IdType="pubmed">32284613</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng S.C., Tilg H. COVID-19 and the gastrointestinal tract: More than meets the eye. Gut. 2020;69:973&#x2013;974. doi: 10.1136/gutjnl-2020-321195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-321195</ArticleId><ArticleId IdType="pmc">PMC7211058</ArticleId><ArticleId IdType="pubmed">32273292</ArticleId></ArticleIdList></Reference><Reference><Citation>Chassaing B., Kumar M., Baker M.T., Singh V., Vijay-Kumar M. Mammalian gut immunity. Biomed. J. 2014;37:246&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4714863</ArticleId><ArticleId IdType="pubmed">25163502</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Kamm M.A., Colombel J.F., Ng S.C. Urbanization and the gut microbiota in health and inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 2018;15:440&#x2013;452. doi: 10.1038/s41575-018-0003-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-018-0003-z</ArticleId><ArticleId IdType="pubmed">29670252</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Liu Q., Zhang F., Yeoh Y.K., Wan Y., Zhan H., Lui G.C.Y., Chen Z., Li A.Y.L., Cheung C.P., et al. Temporal landscape of human gut RNA and DNA virome in SARS-CoV-2 infection and severity. Microbiome. 2021;9:91. doi: 10.1186/s40168-021-01008-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40168-021-01008-x</ArticleId><ArticleId IdType="pmc">PMC8044506</ArticleId><ArticleId IdType="pubmed">33853691</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Zhan H., Zhang F., Liu Q., Tso E.Y.K., Lui G.C.Y., Chen N., Li A., Lu W., Chan F.K.L., et al. Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge. Gastroenterology. 2020;159:1302&#x2013;1310.e5. doi: 10.1053/j.gastro.2020.06.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.06.048</ArticleId><ArticleId IdType="pmc">PMC7318920</ArticleId><ArticleId IdType="pubmed">32598884</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Zhang F., Lui G.C.Y., Yeoh Y.K., Li A.Y.L., Zhan H., Wan Y., Chung A.C.K., Cheung C.P., Chen N., et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020;159:944&#x2013;955.e8. doi: 10.1053/j.gastro.2020.05.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.048</ArticleId><ArticleId IdType="pmc">PMC7237927</ArticleId><ArticleId IdType="pubmed">32442562</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B., Zhang L., Wang Y., Dai T., Qin Z., Zhou F., Zhang L. Alterations in microbiota of patients with covid-19: Potential mechanisms and therapeutic interventions. Signal Transduct. Target. Ther. 2022;7:143. doi: 10.1038/s41392-022-00986-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00986-0</ArticleId><ArticleId IdType="pmc">PMC9052735</ArticleId><ArticleId IdType="pubmed">35487886</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Wu X., Wen W., Lan P. Gut Microbiome Alterations in COVID-19. Genom. Proteom. Bioinform. 2021;19:679&#x2013;688. doi: 10.1016/j.gpb.2021.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gpb.2021.09.004</ArticleId><ArticleId IdType="pmc">PMC8478109</ArticleId><ArticleId IdType="pubmed">34560321</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang L., Gu S., Gong Y., Li B., Lu H., Li Q., Zhang R., Gao X., Wu Z., Zhang J., et al. Clinical Significance of the Correlation between Changes in the Major Intestinal Bacteria Species and COVID-19 Severity. Engineering. 2020;6:1178&#x2013;1184. doi: 10.1016/j.eng.2020.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eng.2020.05.013</ArticleId><ArticleId IdType="pmc">PMC7832131</ArticleId><ArticleId IdType="pubmed">33520333</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu S., Chen Y., Wu Z., Chen Y., Gao H., Lv L., Guo F., Zhang X., Luo R., Huang C., et al. Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza. Clin. Infect. Dis. 2020;71:2669&#x2013;2678. doi: 10.1093/cid/ciaa709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa709</ArticleId><ArticleId IdType="pmc">PMC7314193</ArticleId><ArticleId IdType="pubmed">32497191</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng J., Li Y., Li J., Shen L., Zhu L., Liang Y., Lin X., Jiao N., Cheng S., Huang Y., et al. Gastrointestinal sequelae 90 days after discharge for COVID-19. Lancet Gastroenterol. Hepatol. 2021;6:344&#x2013;346. doi: 10.1016/S2468-1253(21)00076-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(21)00076-5</ArticleId><ArticleId IdType="pmc">PMC7943402</ArticleId><ArticleId IdType="pubmed">33711290</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C., Wang Z., Lorenzi J.C.C., Muecksch F., Finkin S., Tokuyama M., Cho A., Jankovic M., Schaefer-Babajew D., Oliveira T.Y., et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:639&#x2013;644. doi: 10.1038/s41586-021-03207-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Zhang L., Sang L., Ye F., Ruan S., Zhong B., Song T., Alshukairi A.N., Chen R., Zhang Z., et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. J. Clin. Investig. 2020;130:5235&#x2013;5244. doi: 10.1172/JCI138759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI138759</ArticleId><ArticleId IdType="pmc">PMC7524490</ArticleId><ArticleId IdType="pubmed">32634129</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Gu S., Chen Y., Lu H., Shi D., Guo J., Wu W.R., Yang Y., Li Y., Xu K.J., et al. Six-month follow-up of gut microbiota richness in patients with COVID-19. Gut. 2022;71:222&#x2013;225. doi: 10.1136/gutjnl-2021-324090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324090</ArticleId><ArticleId IdType="pmc">PMC8666823</ArticleId><ArticleId IdType="pubmed">33833065</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokol H., Contreras V., Maisonnasse P., Desmons A., Delache B., Sencio V., Machelart A., Brisebarre A., Humbert L., Deryuter L., et al. SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota. Gut Microbes. 2021;13:1&#x2013;19. doi: 10.1080/19490976.2021.1893113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2021.1893113</ArticleId><ArticleId IdType="pmc">PMC7951961</ArticleId><ArticleId IdType="pubmed">33685349</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Mak J.W.Y., Su Q., Yeoh Y.K., Lui G.C., Ng S.S.S., Zhang F., Li A.Y.L., Lu W., Hui D.S., et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. 2022;71:544&#x2013;552. doi: 10.1136/gutjnl-2021-325989.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325989</ArticleId><ArticleId IdType="pubmed">35082169</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Q., Lau R.I., Liu Q., Chan F.K.L., Ng S.C. Post-acute COVID-19 syndrome and gut dysbiosis linger beyond 1 year after SARS-CoV-2 clearance. Gut. 2022. Online ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2022-328319</ArticleId><ArticleId IdType="pubmed">35940857</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y., Xie J.P., Deng K., Li X., Yuan Y., Xuan Q., Xie J., He X.M., Wang Q., Li J.J., et al. Prophylactic Effects of Bifidobacterium adolescentis on Anxiety and Depression-Like Phenotypes After Chronic Stress: A Role of the Gut Microbiota-Inflammation Axis. Front. Behav. Neurosci. 2019;13:126. doi: 10.3389/fnbeh.2019.00126.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnbeh.2019.00126</ArticleId><ArticleId IdType="pmc">PMC6591489</ArticleId><ArticleId IdType="pubmed">31275120</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Z., Wang H., Cui G., Lu H., Wang L., Luo H., Chen X., Ren H., Sun R., Liu W., et al. Alterations in the human oral and gut microbiomes and lipidomics in covid-19. Gut. 2021;70:1253&#x2013;1265. doi: 10.1136/gutjnl-2020-323826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-323826</ArticleId><ArticleId IdType="pmc">PMC8042598</ArticleId><ArticleId IdType="pubmed">33789966</ArticleId></ArticleIdList></Reference><Reference><Citation>Lahti L., Salojarvi J., Salonen A., Scheffer M., de Vos W.M. Tipping elements in the human intestinal ecosystem. Nat. Commun. 2014;5:4344. doi: 10.1038/ncomms5344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms5344</ArticleId><ArticleId IdType="pmc">PMC4102116</ArticleId><ArticleId IdType="pubmed">25003530</ArticleId></ArticleIdList></Reference><Reference><Citation>Buffie C.G., Pamer E.G. Microbiota-mediated colonization resistance against intestinal pathogens. Nat. Rev. Immunol. 2013;13:790&#x2013;801. doi: 10.1038/nri3535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3535</ArticleId><ArticleId IdType="pmc">PMC4194195</ArticleId><ArticleId IdType="pubmed">24096337</ArticleId></ArticleIdList></Reference><Reference><Citation>Finlay B.B., Amato K.R., Azad M., Blaser M.J., Bosch T.C.G., Chu H., Dominguez-Bello M.G., Ehrlich S.D., Elinav E., Geva-Zatorsky N., et al. The hygiene hypothesis, the COVID pandemic, and consequences for the human microbiome. Proc. Natl. Acad. Sci. USA. 2021;118:e2010217118. doi: 10.1073/pnas.2010217118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2010217118</ArticleId><ArticleId IdType="pmc">PMC8017729</ArticleId><ArticleId IdType="pubmed">33472859</ArticleId></ArticleIdList></Reference><Reference><Citation>Vestad B., Ueland T., Lerum T.V., Dahl T.B., Holm K., Barratt-Due A., K&#xe5;sine T., Dyrhol-Riise A.M., Stiksrud B., Tonby K., et al. Respiratory dysfunction three months after severe COVID-19 is associated with gut microbiota alterations. J. Intern. Med. 2022;291:801&#x2013;812. doi: 10.1111/joim.13458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13458</ArticleId><ArticleId IdType="pmc">PMC9115297</ArticleId><ArticleId IdType="pubmed">35212063</ArticleId></ArticleIdList></Reference><Reference><Citation>Nataf S., Pays L. Molecular Insights into SARS-CoV2-Induced Alterations of the Gut/Brain Axis. Int. J. Mol. Sci. 2021;22:10440. doi: 10.3390/ijms221910440.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms221910440</ArticleId><ArticleId IdType="pmc">PMC8508788</ArticleId><ArticleId IdType="pubmed">34638785</ArticleId></ArticleIdList></Reference><Reference><Citation>Santus W., Devlin J.R., Behnsen J. Crossing Kingdoms: How the Mycobiota and Fungal-Bacterial Interactions Impact Host Health and Disease. Infect. Immun. 2021;89:e00648-20. doi: 10.1128/IAI.00648-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.00648-20</ArticleId><ArticleId IdType="pmc">PMC8090948</ArticleId><ArticleId IdType="pubmed">33526565</ArticleId></ArticleIdList></Reference><Reference><Citation>van Tilburg Bernardes E., Pettersen V.K., Gutierrez M.W., Laforest-Lapointe I., Jendzjowsky N.G., Cavin J.B., Vicentini F.A., Keenan C.M., Ramay H.R., Samara J., et al. Intestinal fungi are causally implicated in microbiome assembly and immune development in mice. Nat. Commun. 2020;11:2577. doi: 10.1038/s41467-020-16431-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-16431-1</ArticleId><ArticleId IdType="pmc">PMC7244730</ArticleId><ArticleId IdType="pubmed">32444671</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv L., Gu S., Jiang H., Yan R., Chen Y., Chen Y., Luo R., Huang C., Lu H., Zheng B., et al. Gut mycobiota alterations in patients with COVID-19 and H1N1 infections and their associations with clinical features. Commun. Biol. 2021;4:480. doi: 10.1038/s42003-021-02036-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-02036-x</ArticleId><ArticleId IdType="pmc">PMC8044104</ArticleId><ArticleId IdType="pubmed">33850296</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox M.J., Loman N., Bogaert D., O&#x2019;Grady J. Co-infections: Potentially lethal and unexplored in COVID-19. Lancet Microbe. 2020;1:e11. doi: 10.1016/S2666-5247(20)30009-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(20)30009-4</ArticleId><ArticleId IdType="pmc">PMC7195315</ArticleId><ArticleId IdType="pubmed">32835323</ArticleId></ArticleIdList></Reference><Reference><Citation>Peman J., Ruiz-Gaitan A., Garcia-Vidal C., Salavert M., Ramirez P., Puchades F., Garcia-Hita M., Alastruey-Izquierdo A., Quindos G. Fungal co-infection in COVID-19 patients: Should we be concerned? Rev. Iberoam. Micol. 2020;37:41&#x2013;46. doi: 10.1016/j.riam.2020.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.riam.2020.07.001</ArticleId><ArticleId IdType="pmc">PMC7489924</ArticleId><ArticleId IdType="pubmed">33041191</ArticleId></ArticleIdList></Reference><Reference><Citation>Song G., Liang G., Liu W. Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China. Mycopathologia. 2020;185:599&#x2013;606. doi: 10.1007/s11046-020-00462-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11046-020-00462-9</ArticleId><ArticleId IdType="pmc">PMC7394275</ArticleId><ArticleId IdType="pubmed">32737747</ArticleId></ArticleIdList></Reference><Reference><Citation>Erb Downward J.R., Falkowski N.R., Mason K.L., Muraglia R., Huffnagle G.B. Modulation of post-antibiotic bacterial community reassembly and host response by Candida albicans. Sci. Rep. 2013;3:2191. doi: 10.1038/srep02191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep02191</ArticleId><ArticleId IdType="pmc">PMC3709164</ArticleId><ArticleId IdType="pubmed">23846617</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Wong S.H., Cheung C.P., Lam K., Lui R., Cheung K., Zhang F., Tang W., Ching J.Y.L., Wu J.C.Y., et al. Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection. Nat. Commun. 2018;9:3663. doi: 10.1038/s41467-018-06103-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06103-6</ArticleId><ArticleId IdType="pmc">PMC6131390</ArticleId><ArticleId IdType="pubmed">30202057</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumamoto C.A. Inflammation and gastrointestinal Candida colonization. Curr. Opin. Microbiol. 2011;14:386&#x2013;391. doi: 10.1016/j.mib.2011.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mib.2011.07.015</ArticleId><ArticleId IdType="pmc">PMC3163673</ArticleId><ArticleId IdType="pubmed">21802979</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonoyama K., Miki A., Sugita R., Goto H., Nakata M., Yamaguchi N. Gut colonization by Candida albicans aggravates inflammation in the gut and extra-gut tissues in mice. Med. Mycol. 2011;49:237&#x2013;247. doi: 10.3109/13693786.2010.511284.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/13693786.2010.511284</ArticleId><ArticleId IdType="pubmed">20807027</ArticleId></ArticleIdList></Reference><Reference><Citation>Neil J.A., Cadwell K. The Intestinal Virome and Immunity. J. Immunol. 2018;201:1615&#x2013;1624. doi: 10.4049/jimmunol.1800631.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1800631</ArticleId><ArticleId IdType="pmc">PMC6179364</ArticleId><ArticleId IdType="pubmed">30181300</ArticleId></ArticleIdList></Reference><Reference><Citation>Virgin H.W. The virome in mammalian physiology and disease. Cell. 2014;157:142&#x2013;150. doi: 10.1016/j.cell.2014.02.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.02.032</ArticleId><ArticleId IdType="pmc">PMC3977141</ArticleId><ArticleId IdType="pubmed">24679532</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Liu Q., Zhang F., Lui G.C., Tso E.Y., Yeoh Y.K., Chen Z., Boon S.S., Chan F.K., Chan P.K., et al. Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut. 2021;70:276&#x2013;284. doi: 10.1136/gutjnl-2020-322294.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-322294</ArticleId><ArticleId IdType="pmc">PMC7385744</ArticleId><ArticleId IdType="pubmed">32690600</ArticleId></ArticleIdList></Reference><Reference><Citation>Norman J.M., Handley S.A., Baldridge M.T., Droit L., Liu C.Y., Keller B.C., Kambal A., Monaco C.L., Zhao G., Fleshner P., et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell. 2015;160:447&#x2013;460. doi: 10.1016/j.cell.2015.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.002</ArticleId><ArticleId IdType="pmc">PMC4312520</ArticleId><ArticleId IdType="pubmed">25619688</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Lu X.J., Zhang Y., Cheung C.P., Lam S., Zhang F., Tang W., Ching J.Y.L., Zhao R., Chan P.K.S., et al. Gut mucosal virome alterations in ulcerative colitis. Gut. 2019;68:1169&#x2013;1179. doi: 10.1136/gutjnl-2018-318131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2018-318131</ArticleId><ArticleId IdType="pmc">PMC6582748</ArticleId><ArticleId IdType="pubmed">30842211</ArticleId></ArticleIdList></Reference><Reference><Citation>Diard M., Bakkeren E., Cornuault J.K., Moor K., Hausmann A., Sellin M.E., Loverdo C., Aertsen A., Ackermann M., De Paepe M., et al. Inflammation boosts bacteriophage transfer between Salmonella spp. Science. 2017;355:1211&#x2013;1215. doi: 10.1126/science.aaf8451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf8451</ArticleId><ArticleId IdType="pubmed">28302859</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J., Wang C., Zhang Y., Lei G., Xu K., Zhao N., Lu J., Meng F., Yu L., Yan J., et al. Integrated gut virome and bacteriome dynamics in COVID-19 patients. Gut Microbes. 2021;13:1&#x2013;21. doi: 10.1080/19490976.2021.1887722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2021.1887722</ArticleId><ArticleId IdType="pmc">PMC7946006</ArticleId><ArticleId IdType="pubmed">33678150</ArticleId></ArticleIdList></Reference><Reference><Citation>Tutuncuoglu B., Cakir M., Batra J., Bouhaddou M., Eckhardt M., Gordon D.E., Krogan N.J. The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2. Cancer Discov. 2020;10:916&#x2013;921. doi: 10.1158/2159-8290.CD-20-0559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-20-0559</ArticleId><ArticleId IdType="pmc">PMC7357668</ArticleId><ArticleId IdType="pubmed">32444466</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahimmanesh I., Shariati L., Dana N., Esmaeili Y., Vaseghi G., Haghjooy Javanmard S. Cancer Occurrence as the Upcoming Complications of COVID-19. Front. Mol. Biosci. 2022;8:813175. doi: 10.3389/fmolb.2021.813175.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.813175</ArticleId><ArticleId IdType="pmc">PMC8831861</ArticleId><ArticleId IdType="pubmed">35155571</ArticleId></ArticleIdList></Reference><Reference><Citation>Saini G., Aneja R. Cancer as a prospective sequela of long COVID-19. BioEssays. 2021;43:e2000331. doi: 10.1002/bies.202000331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.202000331</ArticleId><ArticleId IdType="pmc">PMC8206711</ArticleId><ArticleId IdType="pubmed">33914346</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon D.E., Jang G.M., Bouhaddou M., Xu J., Obernier K., White K.M., O&#x2019;Meara M.J., Rezelj V.V., Guo J.Z., Swaney D.L., et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583:459&#x2013;468. doi: 10.1038/s41586-020-2286-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2286-9</ArticleId><ArticleId IdType="pmc">PMC7431030</ArticleId><ArticleId IdType="pubmed">32353859</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatti P., Ilamathi H.S., Todkar K., Germain M. Mitochondria Targeted Viral Replication and Survival Strategies-Prospective on SARS-CoV-2. Front. Pharmacol. 2020;11:578599. doi: 10.3389/fphar.2020.578599.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.578599</ArticleId><ArticleId IdType="pmc">PMC7485471</ArticleId><ArticleId IdType="pubmed">32982760</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy D.M., Walsh L.A., Chan T.A. Driver mutations of cancer epigenomes. Protein Cell. 2014;5:265&#x2013;296. doi: 10.1007/s13238-014-0031-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13238-014-0031-6</ArticleId><ArticleId IdType="pmc">PMC3978161</ArticleId><ArticleId IdType="pubmed">24622842</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Carpizo V., Sarmentero J., Han B., Gra&#xf1;a O., Ruiz-Llorente S., Pisano D.G., Serrano M., Brooks H.B., Campbell R.M., Barrero M.J. NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation. Sci. Rep. 2016;6:32952. doi: 10.1038/srep32952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep32952</ArticleId><ArticleId IdType="pmc">PMC5015087</ArticleId><ArticleId IdType="pubmed">27604143</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun D., Yu M., Li Y., Xing H., Gao Y., Huang Z., Hao W., Lu K., Kong C., Shimozato O., et al. Histone deacetylase 2 is involved in DNA damage-mediated cell death of human osteosarcoma cells through stimulation of the ATM/p53 pathway. FEBS Open Bio. 2019;9:478&#x2013;489. doi: 10.1002/2211-5463.12585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/2211-5463.12585</ArticleId><ArticleId IdType="pmc">PMC6396148</ArticleId><ArticleId IdType="pubmed">30868056</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma-Lauer Y., Carbajo-Lozoya J., Hein M.Y., M&#xfc;ller M.A., Deng W., Lei J., Meyer B., Kusov Y., Von Brunn B., Bairad D.R., et al. p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1. Proc. Natl. Acad. Sci. USA. 2016;113:E5192&#x2013;E5201. doi: 10.1073/pnas.1603435113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1603435113</ArticleId><ArticleId IdType="pmc">PMC5024628</ArticleId><ArticleId IdType="pubmed">27519799</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhardwaj K., Liu P., Leibowitz J.L., Kao C.C. The coronavirus endoribonuclease Nsp15 interacts with retinoblastoma tumor suppressor protein. J. Virol. 2012;86:4294&#x2013;4304. doi: 10.1128/JVI.07012-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.07012-11</ArticleId><ArticleId IdType="pmc">PMC3318636</ArticleId><ArticleId IdType="pubmed">22301153</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N., Bharara Singh A. S2 subunit of SARS-nCoV-2 interacts with tumor suppressor protein p53 and BRCA: An in silico study. Trans. Oncol. 2020;13:100814. doi: 10.1016/j.tranon.2020.100814.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tranon.2020.100814</ArticleId><ArticleId IdType="pmc">PMC7324311</ArticleId><ArticleId IdType="pubmed">32619819</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen K.L., Brockwell N.K., Parker B.S. JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression. Cancers. 2019;11:2002. doi: 10.3390/cancers11122002.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers11122002</ArticleId><ArticleId IdType="pmc">PMC6966445</ArticleId><ArticleId IdType="pubmed">31842362</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Y., Shen S., Verma I.M. NF-&#x3ba;B, an active player in human cancers. Cancer Immunol. Res. 2014;2:823&#x2013;830. doi: 10.1158/2326-6066.CIR-14-0112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2326-6066.CIR-14-0112</ArticleId><ArticleId IdType="pmc">PMC4155602</ArticleId><ArticleId IdType="pubmed">25187272</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Hijano L., Sainz B., Jr. The Interactions Between Cancer Stem Cells and the Innate Interferon Signaling Pathway. Front. Immunol. 2020;11:526. doi: 10.3389/fimmu.2020.00526.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00526</ArticleId><ArticleId IdType="pmc">PMC7136464</ArticleId><ArticleId IdType="pubmed">32296435</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C.H., Murti A., Pfeffer S.R., Basu L., Kim J.G., Pfeffer L.M. IFN&#x3b1;/&#x3b2; promotes cell survival by activating NF-&#x3ba;B. Proc. Natl. Acad. Sci. USA. 2000;97:13631&#x2013;13636. doi: 10.1073/pnas.250477397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.250477397</ArticleId><ArticleId IdType="pmc">PMC17627</ArticleId><ArticleId IdType="pubmed">11095741</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomez D., Reich N.C. Stimulation of primary human endothelial cell proliferation by IFN. J. Immunol. 2003;170:5373&#x2013;5381. doi: 10.4049/jimmunol.170.11.5373.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.170.11.5373</ArticleId><ArticleId IdType="pubmed">12759411</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty G.L., Paterson Y. IFN-&#x3b3; can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J. Immunol. 2000;165:5502&#x2013;5508. doi: 10.4049/jimmunol.165.10.5502.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.165.10.5502</ArticleId><ArticleId IdType="pubmed">11067903</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z., Tao T., Li H., Zhu X. mTOR signaling pathway and mTOR inhibitors in cancer: Progress and challenges. Cell Biosci. 2020;10:31. doi: 10.1186/s13578-020-00396-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13578-020-00396-1</ArticleId><ArticleId IdType="pmc">PMC7063815</ArticleId><ArticleId IdType="pubmed">32175074</ArticleId></ArticleIdList></Reference><Reference><Citation>Farahani M., Niknam Z., Mohammadi Amirabad L., Amiri-Dashatan N., Koushki M., Nemati M., Danesh Pouya F., Rezaei-Tavirani M., Rasmi Y., Tayebi L. Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets. Biomed. Pharmacother. 2022;145:112420. doi: 10.1016/j.biopha.2021.112420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.112420</ArticleId><ArticleId IdType="pmc">PMC8585639</ArticleId><ArticleId IdType="pubmed">34801852</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaiah M.J. mTOR inhibition and p53 activation, microRNAs: The possible therapy against pandemic COVID-19. Gene Rep. 2020;20:100765. doi: 10.1016/j.genrep.2020.100765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genrep.2020.100765</ArticleId><ArticleId IdType="pmc">PMC7324924</ArticleId><ArticleId IdType="pubmed">32835132</ArticleId></ArticleIdList></Reference><Reference><Citation>Breikaa R.M., Lilly B. The Notch Pathway: A Link Between COVID-19 Pathophysiology and Its Cardiovascular Complications. Front. Cardiovasc. Med. 2021;8:681948. doi: 10.3389/fcvm.2021.681948.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.681948</ArticleId><ArticleId IdType="pmc">PMC8187573</ArticleId><ArticleId IdType="pubmed">34124207</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B., Lin W., Long Y., Yang Y., Zhang H., Wu K., Chu Q. Notch signaling pathway: Architecture, disease, and therapeutics. Signal. Transduct. Target. Ther. 2022;7:95. doi: 10.1038/s41392-022-00934-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00934-y</ArticleId><ArticleId IdType="pmc">PMC8948217</ArticleId><ArticleId IdType="pubmed">35332121</ArticleId></ArticleIdList></Reference><Reference><Citation>Misiorek J.O., Przybyszewska-Podstawka A., Ka&#x142;afut J., Paziewska B., Rolle K., Rivero-M&#xfc;ller A., Nees M. Context Matters: NOTCH Signatures and Pathway in Cancer Progression and Metastasis. Cells. 2021;10:94. doi: 10.3390/cells10010094.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10010094</ArticleId><ArticleId IdType="pmc">PMC7827494</ArticleId><ArticleId IdType="pubmed">33430387</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudaravalli S., den Hollander P., Mani S.A. Role of p38 MAP kinase in cancer stem cells and metastasis. Oncogene. 2022;41:3177&#x2013;3185. doi: 10.1038/s41388-022-02329-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41388-022-02329-3</ArticleId><ArticleId IdType="pmc">PMC9166676</ArticleId><ArticleId IdType="pubmed">35501462</ArticleId></ArticleIdList></Reference><Reference><Citation>Grimes J.M., Grimes K.V. p38 MAPK inhibition: A promising therapeutic approach for COVID-19. J. Mol. Cell Cardiol. 2020;144:63&#x2013;65. doi: 10.1016/j.yjmcc.2020.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2020.05.007</ArticleId><ArticleId IdType="pmc">PMC7228886</ArticleId><ArticleId IdType="pubmed">32422320</ArticleId></ArticleIdList></Reference><Reference><Citation>Limoge M., Safina A., Truskinovsky A.M., Aljahdali I., Zonneville J., Gruevski A., Arteaga C.L., Bakin A.V. Tumor p38MAPK signaling enhances breast carcinoma vascularization and growth by promoting expression and deposition of pro-tumorigenic factors. Oncotarget. 2017;8:61969&#x2013;61981. doi: 10.18632/oncotarget.18755.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.18755</ArticleId><ArticleId IdType="pmc">PMC5617479</ArticleId><ArticleId IdType="pubmed">28977919</ArticleId></ArticleIdList></Reference><Reference><Citation>Serebrovska Z.O., Chong E.Y., Serebrovska T.V., Tumanovska L.V., Xi L. Hypoxia, HIF-1&#x3b1;, and COVID-19: From pathogenic factors to potential therapeutic targets. Acta Pharmacol. Sin. 2020;41:1539&#x2013;1546. doi: 10.1038/s41401-020-00554-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-020-00554-8</ArticleId><ArticleId IdType="pmc">PMC7588589</ArticleId><ArticleId IdType="pubmed">33110240</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Tameemi W., Dale T.P., Al-Jumaily R.M.K., Forsyth N.R. Hypoxia-Modified Cancer Cell Metabolism. Front. Cell Dev. Biol. 2019;7:4. doi: 10.3389/fcell.2019.00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2019.00004</ArticleId><ArticleId IdType="pmc">PMC6362613</ArticleId><ArticleId IdType="pubmed">30761299</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>